Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study Comparing Carboplatin and Cisplatin for Patients with Extracranial Malignant Germ Cell Tumors

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Malignant Extracranial Germ Cell Tumors, which are a type of cancer that occurs outside the brain. The trial aims to compare the effectiveness of two chemotherapy drugs, Carboplatin and Cisplatin, in treating these tumors. Both drugs are used to kill cancer cells and are administered through an intravenous method, meaning they are given directly into a vein.

The purpose of the study is to determine if Carboplatin is as effective as Cisplatin in treating patients with these tumors. Participants in the study will receive either Carboplatin or Cisplatin and will be monitored over time to see how well the treatment works. The study will look at how long patients remain free from cancer events, such as tumor growth or recurrence, and will also consider overall survival rates.

Throughout the study, researchers will also assess the safety of the treatments by monitoring any side effects or adverse reactions. Additionally, the study will evaluate other factors such as the number of hospital days required during treatment and the need for blood transfusions. The trial is expected to continue until 2028, providing valuable information on the best treatment options for patients with Malignant Extracranial Germ Cell Tumors.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the trial

    Upon joining the trial, you will be randomly assigned to receive either Carboplatin or Cisplatin as part of your treatment for malignant germ cell tumors.

    This assignment is part of a study to compare the effectiveness of these two medications.

  2. Step 2

    Treatment plan

    If assigned to Carboplatin, you will receive a dose of 600 mg/m² per cycle, administered through an intravenous infusion.

    If assigned to Cisplatin, you will receive a dose of 100 mg/m² per cycle, also administered through an intravenous infusion.

    The treatment cycles will be repeated as per the trial protocol, and your doctor will provide specific details about the frequency and duration.

  3. Step 3

    Monitoring and assessments

    Throughout the trial, regular monitoring will be conducted to assess your response to the treatment.

    This includes checking standard tumor marker levels after each cycle and evaluating any side effects or adverse events.

    Your overall health and any changes in your condition will be closely observed.

  4. Step 4

    Follow-up evaluations

    After completing the treatment cycles, follow-up evaluations will be conducted to determine the effectiveness of the treatment.

    These evaluations will include imaging tests and possibly additional laboratory tests to check for any remaining tumor cells or changes in your condition.

  5. Step 5

    End of trial participation

    Your participation in the trial will conclude after the final follow-up evaluations are completed.

    The results of your treatment will contribute to the overall findings of the study, which aims to improve treatment options for patients with malignant germ cell tumors.

Who can join the trial?

5 criteria

  • Confirmed extracranial MGCT (Malignant Germ Cell Tumours outside the brain) up to 17 years and 11 months of age, or patients with ovarian primaries up to 29 years and 11 months of age on the date of written informed consent.
  • Diagnosis of a chemotherapy-naïve extracranial MGCT, meaning the patient has not received chemotherapy treatment for this condition before.
  • Written informed consent from patients and/or their parents according to national law before joining the trial.
  • Karnofsky Index of more than 70% or ECOG Status of 0-II. These are scales used to measure the patient's ability to perform daily activities. A higher score means the patient is more capable.
  • Negative pregnancy test within 7 days before starting treatment for female patients who can have children. If the MGCT secretes a hormone called ß-HCG, pregnancy must be ruled out using appropriate methods.

Who cannot join the trial?

7 criteria

  • Patients with other types of cancer that are not Malignant Extracranial Germ Cell Tumours (MGCT).
  • Patients who have previously received treatment with Carboplatin or Cisplatin for MGCT.
  • Patients with severe kidney problems, as these drugs can affect kidney function.
  • Patients with severe hearing problems, as these drugs can affect hearing.
  • Patients who are pregnant or breastfeeding, as the drugs may harm the baby.
  • Patients who are unable to follow the study procedures or attend follow-up visits.
  • Patients with any other medical condition that the study doctors think would make it unsafe for them to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Carboplatin

    is a medication used in this clinical trial to treat certain types of cancer, specifically malignant germ cell tumors. It works by interfering with the DNA in cancer cells, which prevents them from growing and dividing. This medication is being tested to see if it is as effective as another drug, Cisplatin, in helping patients live longer without the cancer coming back.

  • Cisplatin

    is another medication used in the trial for treating malignant germ cell tumors. Like Carboplatin, it also targets the DNA of cancer cells, stopping them from multiplying. The trial aims to compare Cisplatin with Carboplatin to determine which one is more effective in preventing the return of cancer in patients with these tumors.

What is already known about the treatment

  • Carboplatin

    Carboplatin is administered intravenously, meaning it is given through a vein, typically in a hospital or clinic setting. It is currently being studied in clinical trials for its effectiveness in treating malignant extracranial germ cell tumors (MGCT), which are a type of cancer. The main therapeutic use of Carboplatin is to treat these tumors, and it works by interfering with the DNA of cancer cells, preventing them from growing and dividing. It belongs to a class of drugs known as platinum-based chemotherapy agents.

  • Cisplatin

    Cisplatin is also administered intravenously, similar to Carboplatin, and is used in medical settings. It is a well-established medication in the treatment of various cancers, including malignant extracranial germ cell tumors (MGCT). Cisplatin's primary therapeutic role is to combat these tumors by binding to DNA in cancer cells, which disrupts their function and leads to cell death. It is classified as a platinum-based chemotherapy drug, known for its effectiveness in cancer treatment.

Investigated diseases

Malignant Extracranial Germ Cell Tumors – These are a type of cancer that originates from germ cells, which are cells that develop into sperm or eggs. They occur outside the brain and spinal cord, often in areas like the abdomen, chest, or pelvis. The disease can grow and spread to other parts of the body, including lymph nodes and distant organs. As the tumor progresses, it may cause symptoms such as pain, swelling, or a noticeable mass. The progression can vary, with some tumors growing slowly while others may advance more rapidly. The disease is categorized into different risk groups based on factors like tumor size and spread, which can influence its progression.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-507582-25-00Protocol codePAED-201601Estimated enrolment360 patientsSponsorRheinische Friedrich-Wilhelms-Universitaet Bonn

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).